Normalized Serum Calcium and Maintained Tacrolimus Levels by Cinacalcet Use in Kidney Transplant Recipients

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Persistent hyperparathyroidism post-kidney transplant is a risk for cardiovascular disease and graft dysfunction.
• Cinacalcet, a calcimimetic, is used in dialysis patients but its role in transplant recipients is unclear.

Purpose of the Study:

• To evaluate the efficacy and safety of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
• To assess changes in calcium, phosphate, and parathyroid hormone levels.
• To determine the effect on tacrolimus trough levels.

Main Methods:

• Prospective cohort study of kidney transplant recipients (KTRs) with hyperparathyroidism (iPTH >65 pg/mL) at least 1 year post-transplant.
• Participants received cinacalcet 25 mg/day for 3 months.
• Primary outcomes: serum calcium, phosphate, iPTH; Secondary outcome: tacrolimus levels.

Main Results:

• Thirty KTRs completed the study. Cinacalcet significantly reduced serum calcium (10.1 to 9.2 mg/dL) and increased serum phosphate (2.7 to 3.0 mg/dL).
• Intact parathyroid hormone (iPTH) levels showed no significant change (median 176.2 vs 178.3 pg/mL).
• Tacrolimus trough levels remained stable (mean 5.9 vs 5.7 ng/mL).

Conclusions:

• Cinacalcet can normalize serum calcium levels in KTRs with persistent hyperparathyroidism.
• Cinacalcet appears safe concerning tacrolimus levels in this population.
• Long-term data, particularly on cardiovascular outcomes, are needed for further evaluation.